Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34902530

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Hepatol
Publication date
2022 Apr
First author
Cheng AL

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Dig Liver Dis. 2022 Nov;54(11):1563-1572. doi: 10.1016/j.dld.2022.07.003.
    note
    Source null
    related pmid
    35906166
    relationship
    Comment in

Authors and identifiers

  1. name
    Cheng AL
    type
    Author
  2. name
    Qin S
    type
    Author
  3. name
    Ikeda M
    type
    Author
  4. name
    Galle PR
    type
    Author
  5. name
    Ducreux M
    type
    Author
  6. name
    Kim TY
    type
    Author
  7. name
    Lim HY
    type
    Author
  8. name
    Kudo M
    type
    Author
  9. name
    Breder V
    type
    Author
  10. name
    Merle P
    type
    Author
  11. name
    Kaseb AO
    type
    Author
  12. name
    Li D
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Cheng AL
    type
    Author
  2. name
    Qin S
    type
    Author
  3. name
    Ikeda M
    type
    Author
  4. name
    Galle PR
    type
    Author
  5. name
    Ducreux M
    type
    Author
  6. name
    Kim TY
    type
    Author
  7. name
    Lim HY
    type
    Author
  8. name
    Kudo M
    type
    Author
  9. name
    Breder V
    type
    Author
  10. name
    Merle P
    type
    Author
  11. name
    Kaseb AO
    type
    Author
  12. name
    Li D
    type
    Author
bibliography ids
  1. nci-bib-ab110b7a55e20e80575d078e
book metadata
content sha256
674ca8202b0e6c126be1b699caac5665c5f9e86a2e85389b8b5f65fa2f49e839
document type
citation
dois
  1. 10.1016/j.jhep.2021.11.030
electronic publication date
display
2021 Dec 11
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34902530
immutable id
pubmed:34902530@674ca8202b0e6c126be1b699caac5665c5f9e86a2e85389b8b5f65fa2f49e839
journal
abbreviation
J Hepatol
issn electronic
1600-0641
issn print
0168-8278
issue
4
name
Journal of hepatology
nlm unique id
8503886
pages
862-873
volume
76
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Dig Liver Dis. 2022 Nov;54(11):1563-1572. doi: 10.1016/j.dld.2022.07.003.
    note
    Source null
    related pmid
    35906166
    relationship
    Comment in
outcomes validated
false
pmid
34902530
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
276f41d70aa5aa99d3d161a003b9575fb6fe0fdcd36e4e700990f41db4474504
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Apr
precision
month
year
2022
publication types
  1. Journal Article
  2. Randomized Controlled Trial
  3. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34902530/
title
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

Preserved source evidence · Not medical advice